DOCSLIB.ORG

Extracorporeal Photopheresis Application Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Extracorporeal Photopheresis Application Update Extracorporeal Photopheresis Application Update Dr. Hind AlHumaidan, MD,FRCPA Consultant Hematopathologiest Director, Blood Bank, Donor, Transfusion Services, APHERESIS & Stem Cell Cord Blood Bank Saudi Arabia chairperson of AATM Extracorporeal Photopheresis • Immune modulating therapy majorly targeting the T cells of the Immune system. • ECP induces an anti-inflammatory condition with tolerogenic responses without inducing a global immunosuppression state. • Clinical indication of ECP has grown over time Extracorporeal Photopheresis • Edelson et al first scientists to develop ECP as a treatment for patients with CTCL. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G N Engl J Med. 1987 Feb 5; 316(6):297-303. • 1988, the FDA, approved the use of ECP standard therapy Extracorporeal Photopheresis ECP has been applied as a treatment modality for several autoimmune T-cell mediated conditions: • Pemphigus vulgaris • systemic sclerosis • rheumatoid arthritis • Crohn's disease • multiple sclerosis ECP • Solid organ allograft rejections. • Acute and chronic graft-versus-host disease. Extracorporeal Photopheresis HISTORY: • Origin of ECP dates back to ancient Egypt (Pharaoh). • People with vitiligo ingested a plant (Ammi majus) found on the banks of the Nile river. • Bathed in the sun, and noticed recovery in melanin production. Extracorporeal Photopheresis Cont. HISTORY: • Psoralen (8-methoxypsoralen [8-MOP]) is inert photo-reactive substance isolated from these plants. • Ultraviolet –A (UVA ) • PUVA treatment. Extracorporeal Photopheresis Technical Aspects: Extracorporeal Photopheresis Asian J Transfus Sci. 2017 Jul-Dec: 11(2): 81-68 Machines for ECP ➢ Two machines for ECP were developed by Therakos and approved by FDA: • Uvar XTS - “second generation discontinuous flow instrument” • Cellex - “third generation continuous flow instrument” Instrument Comparison UVAR XTS • Discontinuous flow • Minimum weight: 40kg • Off-label fluid boluses / blood prime for low TBV • Longer average run time • Lower collection efficiency Instrument Comparison CELLEX • Continuous or discontinuous flow • weight limit 20 kg and above • manufacturer approved volume prime for low TBV • Shorter average run time • Improved collection efficiency compared to UVAR. Extracorporeal Photopheresis Mechanism of Action: Mechanism resulting in the therapeutic activity of ECP is under investigation. • Theories: • ECP affect primarily the T-cell component of the immunological activity. • upregulation of the immune system in cases of CTCL. • downregulation in cases of graft-versus-host disease (GVHD) post transplant and in cases of solid organ allograft rejection. Extracorporeal Photopheresis Mechanism of Action: Extracorporeal Photopheresis • The photoactivated 8-MOP binds to pyrimidine bases of DNA resulting in cross-linking of the two DNA strands induces apoptosis along activating (APC) • 5%–15% of treated mononuclear cells undergo apoptosis on reinfusion • mainly localize in spleen or liver Extracorporeal Photopheresis Scope in Saudi Arabia: • Allogenic bone marrow transplants (BMTs) are increasingly offered by tertiary care centers like our centers. • Availability of unrelated donor marrow registries & haploidentical transplants. • Field is growing. Extracorporeal Photopheresis Extracorporeal Photopheresis • As we grow our center has to offer treatment post transplant complications GvHD. • ECP novel treatment option. • Our center first to install in the region. Extracorporeal Photopheresis • Steroids are the only treatment option available to treat these complications. • ECP offers reduction in alloreactivity in acute and chronic GvHD without global immunosuppression on the contrary of steroids GRAFT-VERSUS-HOST DISEASE (GVHD) Incidence: Post allogeneic HSCT: • aGVHD Grade II-IV 10-60% • cGVHD Moderate-severe 6-80% GRAFT-VERSUS-HOST DISEASE (GVHD) • GVHD remains a major cause of morbidity and mortality following HSCT. • aGVHD occurs before day 100. • Inflammatory tissue injury & necrosis with skin and gastrointestinal (GI) tract inflammation, cholangiohepatic liver injury & cholestatic jaundice. GRAFT-VERSUS-HOST DISEASE (GVHD) • cGVHD after 100 days typically affects skin, GI, liver, lungs, oropharynx, eyes, genital tract and/or musculoskeletal systems without aGVHD features. GRAFT-VERSUS-HOST DISEASE (GVHD) • aGVHD results activation donor T cells by host APCs, leading T cell and cytokine-mediated tissue injury. • cGVHD is due dysregulated allo- or autoreactive T cells, B cells, APCs and NK cells leading fibrosis, inflammation, sclerosis & atrophy tissues. GRAFT-VERSUS-HOST DISEASE (GVHD) Management • aGVHD grade II-IV tx corticosteroids & calcineurin inhibitors. • 5% pt not completely respond. GRAFT-VERSUS-HOST DISEASE (GVHD) Management • cGVHD managed corticosteroids ± other systemic immunosuppressive therapies. • SR or SD extensive cGVHD include other immunosuppressive therapies and ECP. GRAFT-VERSUS-HOST DISEASE (GVHD) Mechanism • ECP works ↥ dendritic cell differentiation, ↧ regulation of autoreactive B cells, alterations in Th & lymphocyte homing antigen display. • Switch from proinflammatory to anti-inflammatory cytokine production, & generation of Treg. GRAFT-VERSUS-HOST DISEASE (GVHD) Overall response rates for SR aGVHD: • reportedly range 52-100%. 66-100% skin. 40-83% GI tract. 27-71% in liver. • Multicenter comparative analysis ECP Verses anticytokine therapy in SR aGVHD reported Higher response in ECP 66% versus 32% (Jagasia ,2013) • Authors suggested earlier use ECP acute phase of inflammation improve complete response rate. GRAFT-VERSUS-HOST DISEASE (GVHD) Overall response rates for SR cGVHD: Variable • Skin 74%. • Liver 68%. • Ocular 60%. • Oral 72%. • Lunge 48% • GI 53% (Malik ,2014) GRAFT-VERSUS-HOST DISEASE (GVHD) • Non-Blinded Assessment Difference recorded 40% complete & partial response in ECP compered 10% non-ECP ,steroids quickly tapered in ECP group. (Flowers,2008) • Randomized study after 24-weeks course ECP showed skin response 33%,extracutaneous tissue 70% suggesting prolonged ECP necessary optimal therapeutic effect. (Greinix, 2011) GRAFT-VERSUS-HOST DISEASE (GVHD) • Maximal responses for cGVHD require 2-6 months of treatment. • Steroid sparing effect occurs even in absence of organ improvement, improves quality of life. • ECP improve/slow lung function decline in cGVHD patients with bronchiolitis obliterans syndrome (BOS) after standard treatment failure. • Recommend consideration of ECP as adjunctive first-line modality for GVHD associated BOS. Journal of Clinical Apheresis (2019) ECP Indications Category I: • Cutaneous T Cell lymphoma (CTCL) Category II: • Graft vs host disease (GVHD) • Acute • Chronic • Solid organ transplant rejection or prophylaxis • Heart • Lung ECP Indications Category III • Atopic dermatitis • Crohn’s disease • Nephrogenic systemic fibrosis • Pemphigus vulgaris • Psoriasis • Scleroderma • Liver solid organ desensitization / rejection Categorized NOT • Kidney • Ulcerative colitis Establishment of ECP Program in KFSH&RC Establishment of ECP Program in KFSH&RC • ECP Program in KFSH&RC started in 2008 to February 2014 • Uvar XTS Machine x 1 • Total of 30 patients o 22 GvHD o 7 CTCL o 1 Lung Transplant Establishment of ECP Program in KFSH&RC • Protocol total of 18 sessions 1st 3 months: 2 sessions back/back bi-weekly 2nd 3 months: 2 sessions back/back monthly ECP Program at KFSH&RC Program stopped due to logistic reasons. ECP Program • Program re-started on August 2016 & renewed October 2019. • Machine Cellex x 3 Advantages of Cellex • Smaller Extracorporeal Volume (ECV) • Shorter procedure times • Procedure both machines not specify lower limit patients WT, HCT, other laboratory parameters. Advantages of Cellex • Users must determine patient safe ECV based on protocol blood volume and HCT using tables procedure manual • No recommended quality control ECP Patients Currently, we now have a total of 75 patients • Adult patients o GvHD – 49 patients o Dermatology – 11 patients o Organ Transplant – 3 patients • Low weight patients – 12 patients ECP Patients • GVHD -55 • Dermatology-11 SEZARY-5 Mycosis-1 Scleroderma-1 Morphea -2 pemphigus Vulgaris-1 • ORGAN TX- Lung Rejection -3 Extracorporeal Photopheresis Heterogeneity of protocols and length of ECP in literature “lack (RCTs)” Protocol for Adult Patients • We started with a total of 18 sessions with the previous protocol and modified to 24 sessions. Adults: Q1 week 2 sessions back/ back 1 month: 8 Q2 week – 2 sessions back / back 2 month: 8 sessions Q month –2sessions 4 month: 8 sessions Protocol for Pediatric Patients • Protocol for pediatric patients 22 sessions Low weight patients: Q1 week – 2 sessions back/back 1 month: 8 sessions Q2 week –2 sessions back/back 2 month: 8 sessions Q month –2 sessions back/back 3 month: 6 sessions Pediatric ECP • Apheresis in children is technically challenging • Low weight patients ECP distinct adult ECP o Significant fluid shift o Vascular Access o Hematologic and metabolic disturbances require close monitoring o Sedation of infants and toddlers Extracorporeal Photopheresis Patient Preparation for ECP and Follow-Ups: • Each session of ECP is an invasive procedure • Patient variables to be assessed for the initiation of therapy: – hemoglobin level (>10 g/dl) – platelets count (>20 × 109/L) – weight (>20 kg) Extracorporeal Photopheresis Post Session: • Patient should be prescribed high SPF sun cream (15 or above) • UVA sunglasses (for 48 h post each session) Extracorporeal
Load more

Recommended publications
  • Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease
    Request for Medicare National Coverage Determination: Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Submitted by: Therakos Inc. 437 Creamery Way Exton, PA 19341 Contact information: Dennis DeCola VP of Compliance and Scientific Affairs Tel: 610-280-1004 Fax: 610-280-1087 E-Mail: [email protected] Request for National Coverage Determination Extracorporeal Photopheresis for Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Page 1 Statement of request Under the National Coverage Determination process, Therakos requests that CMS ex- pand its coverage of Extracorporeal photopheresis (ECP) to include extensive chronic graft-versus-host disease (cGVHD) that has failed to respond to corticosteroids and standard immunosuppressive drug therapy. Specifically, we propose coverage criteria that qualifying Medicare-eligible patients have documented extensive cGVHD that is re­ fractory or resistant to conventional immunosuppressive drug therapy, or are corticoster­ oid-dependent and require dose reduction to abrogate or diminish the risk of infectious or other complications related to high-dose corticosteroid and other immunosuppressive drug therapy. This application of photopheresis is (1) supported by an extensive publication record which documents both efficacy in achieving durable remissions and steroid- and drug- sparing benefit, (2) is widely used in clinical practice in the U.S., and (3) is almost uni­ versally covered by commercial U.S. insurers for the privately insured non-Medicare population. Description of the extracorporeal photopheresis procedure Extracorporeal photopheresis (ECP), also sometimes referred to as extracorporeal photo- chemotherapy, is a highly specialized procedure designed to induce apoptosis in ap­ proximately 10-15% of circulating T-lymphocytes and other leukocytes captured in the buffy coat phase of the patient’s blood.
    [Show full text]
  • Immunological Mechanisms of Extracorporeal Photopheresis in Cutaneous T Cell Lymphoma and Graft Versus Host Disease
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2012 IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE Lisa Shiue Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Immunopathology Commons, Immunoprophylaxis and Therapy Commons, Medicine and Health Sciences Commons, and the Other Immunology and Infectious Disease Commons Recommended Citation Shiue, Lisa, "IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 327. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/327 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE by Lisa Harn-Ging Shiue, B.S. APPROVED: ________________________________________ Madeleine Duvic, M.D., Supervisory Professor _______________________________ Amin Alousi, M.D. ________________________________ Wei Cao, Ph.D. _________________________________ Dorothy Lewis, Ph.D. ______________________________ Greg Lizee, Ph.D.
    [Show full text]
  • ECP) (ECP) • Review ECP Side-Effects, Patient Education and Hazardous Drug Aspects
    12/10/2014 Objectives Acute Graft-Versus-Host Disease • Explain the mechanics of extracorporeal and Extracorporeal Photopheresis photopheresis (ECP) (ECP) • Review ECP side-effects, patient education and hazardous drug aspects LCDR Tracey Chinn, RN, BSN, MPM • Discuss therapy impact to the Clinical Assistant to the Chief, ETIB, NCI inpatient/outpatient Nurse Technical Considerations: Technical Considerations Apheresis Instrument • Cellex (Therakos, Inc.) ▫ Single and double venous access • Uvar XTS (Therakos, Inc.) ▫ Single venous-access only ▫ Current NIH instrument ECP: The Mechanics Technical Considerations: Venous Access 1. Blood is drawn and separated thru centrifugation; WBC are separated and • Apheresis specialist should perform venous collected assessment and make recommendations 2. Plasma and RBCs returned to patient 3. Methoxsalen (Uvadex®) added to the WBC • Peripheral Venous Access 4. Medicated WBC cells exposed to UVA light, ▫ Average needle size = 17-18 gauge which activates the medication ▫ Needle is placed and removed at time of therapy 5. Treated WBC returned to patient; prompt an immune response 1 12/10/2014 Technical Considerations: Technical Considerations: Venous Access Extracorporeal Volume (ECV) • CVAD Access • ECV = Safe mL/whole blood can be taken out of ▫ Typical catheter/size = 9.6 french single-lumen body at one period of time Hickman ▫ NURS – CVAD Flushing Guidelines: “Dialysis/Apheresis –All Purpose Use” • ECV < 15% TBV (Total Blood Volume) ▫ Preference = Use ONLY for therapy • ECV is directly related to: ▫ Safety / Bowl size / Blood prime (< 20 kg) ▫ # Cycles performed = # WBC treated Technical Considerations: Technical Considerations: Extracorporeal Volume (ECV) Extracorporeal Volume (ECV) • Average adult total blood volume = 7- 8% of • Example: body weight ▫ 55 kg (weight) x 70 mL/kg = 3850 mL (TBV) • TBV = patient weight (kg) x body build (mL/kg) ▫ 3850 mL (TBV) x 0.15 = 577 mL (ECV) ▫ Normal build = 70 mL/kg of body weight ▫ Varies based on body build (i.e.
    [Show full text]
  • Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log
    Clinical Policy: Photopheresis (Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Extracorporeal photochemotherapy (ECP), also called photopheresis, is a cell-based immunomodulatory therapy that involves collecting leukocytes from peripheral blood. These cells are exposed to a photosensitizing agent, 8-methoxypsoralen, and are then treated with ultraviolet radiation, after which they are re-infused. This procedure, which results in crosslinking of pyrimidine bases in DNA, produces massive apoptosis of the treated cells. The mechanism of action has not been fully elucidated, however, it is likely that photopheresis activates antigen-presenting cells, such that tumor-related antigens are more readily presented to cytoxic T cells. Policy/Criteria I. It is the policy of Health Net of California that extracorporeal photochemotherapy/photopheresis is medically necessary for the treatment of any of the following: A. Advanced or refractory erythrodermic variants of cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sézary’s syndrome); B. Treatment or prevention of acute or chronic graft-versus-host disease refractory to standard immunosuppressive therapy; C. Heart or heart-lung transplant rejection when rejection episodes are refractory to high- dose steroids plus two or more of the following, unless contraindicated: 1. Cyclosporine; 2. Azathioprine; 3. Methotrexate; 4. Polyclonal and monoclonal antilymphocyte agents (e.g., antilymphocyte globulin ALG], antithymocyte globulin [ATG], OKT3 [monoclonal T-cell antibody]); D. Lung transplant rejection in individuals who are refractory to or intolerant of standard therapy. II.
    [Show full text]
  • Current Research of Extracorporeal Photopheresis and Future
    Extracorporeal Photopheresis are then dispatched to the infected site. For example, the foliative dermatitis, and adenopathy (inflammation of the Current Research of Extracorporeal Photopheresis and Th-1 response is mediated by CD4+ helper T-cells and lymph nodes). Patients with SS do not have a good prog- Future Applications CD8+ T-5 cells that secrete IFN-γ, IL-2, and IL-12 to fight nosis; there is an average survival rate of only 3 years against viruses. The CD4+ helper cells then “help” to in- (Scarisbrick, et al, 2001). SS patients have been found to Chaim Lederer voke a cytotoxic attack against the virus, mainly through have a high rate of Staph colonization. Secondary and hos- CD8+ cytotoxic T-cells (Steinman, Hemmi, 2006) pital acquired infections, most often from Staphylococcus Abstract (Kadowaki, 2007) . aureus (Staph) sepsis due to an impaired immune system, breaks in the skin and use of catheters are particularly fatal Photopheresis, also known as Extracorporeal Photopheresis (ECP) is making inroads in treatment of previously untreata- Located in the immune system, T-regulatory cells in SS patients. The cause of SS is unknown and the diag- ble diseases. As the medical world has delved deeper into, Although the mechanisms of photopheresis are largely un- (T-regs) regulate a wide variety of immune cells such as nosis is very difficult due to its similarities to other skin ail- known, increasingly detailed studies have proven its efficacy. The lack of side effects has made photopheresis an ideal CD4+, CD8+, B-cells, natural killer T-cells, and antigen pre- ments. It was originally believed that SS was derived from option for patients.
    [Show full text]
  • The Need for Individualized Procedures in ECP, the European Perspective!
    The Need for Individualized Procedures in ECP, the European Perspective! Volker Witt, MD St. Anna Kinderspital, Vienna, Austria ECP = extrcorporeal photopheresis 1 2 3 4 15.01.2015 2 What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Preparing a buffy coat • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Apheresis • Preparing a buffy coat • Inline systems • Offline systems • Adding a Photosensitizer • To draw peripheral blood • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Directly from the Apheresis • Preparing a buffy coat device • Adding a Photosensitizer • Diluted by plasma • Transferring in a irradiation • Diluted by saline solution disposable • Hematocrit • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • 8-MOP • Preparing a buffy coat • Final concentration (?) • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Chamber • Preparing a buffy coat • Bag • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • In a pivoting a bag • Preparing
    [Show full text]
  • Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan A
    Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 12-2015 Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD) Bryan A. Sisk Washington University School of Medicine in St. Louis Follow this and additional works at: http://digitalcommons.wustl.edu/kidneycentric_all Recommended Citation Sisk, Bryan A., "Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD)" (2015). Kidneycentric. Paper 11. http://digitalcommons.wustl.edu/kidneycentric_all/11 This Article is brought to you for free and open access by the Kidneycentric at Digital Commons@Becker. It has been accepted for inclusion in Kidneycentric by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan Sisk, MD 7/18/2015 History: The first investigational study on the use of extracorporeal photopheresis (ECP) was published in 1987, and focused on treatment of cutaneous T-cell lymphoma.1 This study led the FDA to approve of photopheresis. Although T-cell lymphoma is the only FDA approved indication for photopheresis its therapeutic use has expanded to a number of other disease processes, most notably acute and chronic graft versus host disease (GVHD). Photopheresis Procedure: ECP is a leukapheresis-based therapy. Whole blood is processed outside of the body in the following way: whole blood is drawn from a catheter placed in a central vein; using centrifugation the different constituents of blood are separated based upon density i.e. white blood cells (WBC) separate into the buffy coat which can distinguished from red blood cells (RBCs) and plasma.2 The RBCs and plasma are returned to the patient, but the buffy coat containing the WBCs is isolated (it should be noted that only 5-10% of the patients WBCs are typically captured during the procedure).
    [Show full text]
  • Extracorporeal Photopheresis Practice Patterns: an International Survey by the ASFA ECP Subcommittee
    Received: 2 May 2016 | Revised: 30 June 2016 | Accepted: 1 July 2016 DOI 10.1002/jca.21486 RESEARCH ARTICLE Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee Nancy M. Dunbar1 | Jay S. Raval2 | Andrew Johnson3 | Cori M. Abikoff4 | Jill Adamski5 | Laura L. Cooling6 | Brenda Grossman7 | Haewon C. Kim8 | Marisa B. Marques9 | Shanna Morgan3,10,11 | Amy E. Schmidt12 | Steven R. Sloan13 | Leon L. Su14 | Zbigniew M. Szczepiorkowski1,17 | F. Bernadette West4 | Edward Wong15 | Jennifer Schneiderman16 1 Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Abstract Center, Lebanon NH Background: Although many apheresis centers offer extracorporeal photopheresis 2 Department of Pathology and Laboratory Medicine, University of North Carolina, (ECP), little is known about current treatment practices. Chapel Hill, NC Methods: An electronic survey was distributed to assess ECP practice 3 Department of Laboratory Medicine and Pathology, University of Minnesota, internationally. Minneapolis, MN Results: Of 251 responses, 137 met criteria for analysis. Most respondents were 4 Department of Pediatrics, New York from North America (80%). Nurses perform ECP at most centers (84%) and the Medical College, Valhalla, NY majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/ 5 Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ year (83%) and perform fewer than 300 procedures/year (70%). Closed system 6 Department of Pathology, University of devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The Michigan School of Medicine, Ann Arbor, most common indications for ECP are acute/chronic skin graft versus host disease MI (89%) and cutaneous T-cell lymphoma (63%).
    [Show full text]
  • Cryopreservation As a Way to Maintain Extracorporeal Photopheresis Regimen for Gvhd Treatment While Circumventing Patient Temporary Inability to Undergo Apheresis
    Bone Marrow Transplantation (2017) 52, 167–170 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/17 www.nature.com/bmt LETTER TO THE EDITOR Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis Bone Marrow Transplantation (2017) 52, 167–170; doi:10.1038/ Nucleated cells were quantified using the pocH-100i device bmt.2016.240; published online 19 September 2016 (Sysmex, Villepinte, France). Cell viability was analyzed by flow cytometry using 7-aminoActinomycin D. CD3+ and CD14+ cells were quantified by FACS analysis, only in the Nancy center. Extracorporeal photopheresis (ECP) is a safe treatment in patients In both centers, the same treatment regimen was used with at with mild acute or chronic GvHD.1–3 However, its clinical use is least 3 ECP (fresh or ‘cryo-ECP’) per week for acute GvHD, and 1 sometimes limited by logistical problems that compromise or 2 ECP per week (depending on GvHD grade) for chronic or late repeated aphereses, especially venous access failure. acute GVHD, until clinical improvement. Merlin et al.4 previously concluded that cryopreservation The clinical severity of acute GvHD was determined as defined 5 before irradiation did not impair WBC functional capabilities. in the 1994 consensus conference criteria. The severity of chronic The hematopoietic stem cell transplantation (HSCT) centers of GvHD was determined as per the 2005 National Institutes of 6 Nancy and Clermont-Ferrand (CF) University Hospitals Health (NIH) consensus guidelines. Response was retrospectively investigated the use of frozen and thawed WBC (FTWBC, assessed at 1, 3 and 6 months in all patients.
    [Show full text]
  • ECP) in the Treatment of Chronic Graft- Versus-Host Disease (GVHD
    Bone Marrow Transplantation, (1999) 23, 881–887 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Extracorporeal photopheresis (ECP) in the treatment of chronic graft- versus-host disease (GVHD) FJ Child1, R Ratnavel1, P Watkins1, D Samson2, J Apperley2, J Ball3, P Taylor3 and R Russell-Jones1 1Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London; 2Department of Haematology, Hammersmith Hospital, London; and 3Department of Haematology, Rotherham District General Hospital, Rotherham, UK Summary: morbidity and mortality. Acute GVHD affects 40–50% of allogeneic stem cell transplant recipients and chronic The aim of our study was to assess the efficacy of extra- GVHD affects 30–50% of those surviving the acute phase corporeal photopheresis (ECP) in chronic graft-versus- of transplantation.1,2 host disease (GVHD). Eleven patients with chronic Prevention of GVHD is important because treatment of cutaneous GVHD were studied. Four had mucosal established disease is often unsatisfactory. Measures such involvement and five had pulmonary involvement. All as pre-transplant T cell depletion and immunosuppression had failed to improve on first- and second-line therapy. with methotrexate, cyclosporin A and prednisolone are Three patients received ECP alone; the remainder con- routinely undertaken. tinued to receive steroids and/or immunosuppressive Chronic GVHD may be limited to localised skin involve- therapy. Patients received ECP twice monthly for 4 ment and liver dysfunction, or the disease may be more months and then once monthly for 3 months. They were extensive with generalised skin involvement and additional evaluated by serial skin scores, mucosal and skin pho- organ involvement.
    [Show full text]
  • The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome
    The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome Selim M. Arcasoy, M.D. Medical Program Director Lung Transplantation Program NewYork-Presbyterian Hospital Columbia University Medical Center New York, NY Terminology/Definitions • OB=BO: Obliterative bronchiolitis or bronchiolitis obliterans • Histopathologic term used to describe the finding of fibrous obliteration of small airways after LTx • BOS: Bronchiolitis obliterans syndrome • Clinical/physiologic definition of chronic lung allograft dysfunction caused by OB and characterized by progressive airflow limitation • Term originally proposed in 1993 and revised in 2002 Bronchiolitis Obliterans Syndrome Clinical Impact Very common and deadly • Cumulative risk of 50-80% between 5 and 10 years after lung transplantation • Leading cause of long-term mortality • Directly or indirectly accounts for at least 30 to 50% of deaths after third post-operative year • Less than 40% survival at 5 years after its onset Injury to airway epithelium Normal Alloimmune or non-alloimmune Pathogenesis of OB (rejection, infection, aspiration, ischemia) Inflammatory response Vascular changes Innate and adaptive immune response (PMN, macrophage, DC, T- and B-lymphocytes) Final common pathway IL-1, IL-2, IL-6, IL-8, IL-12, Repair response TNF-α, MCP-1, complement, Fibroblast proliferation IFN-γ, RANTES, ROS, NO, EC matrix deposition peroxides, leukotrienes TGF-ß,PDGF, IGF, FGF, ET-1 Mechanisms and Therapy of OB After Lung Tx Adapted from Nicod. Proc Am Thorac Soc 2006;3:444 Irritants/
    [Show full text]
  • Extracorporeal Photopheresis
    Medical Coverage Policy Effective Date ............................................05/15/2021 Next Review Date ......................................05/15/2022 Coverage Policy Number .................................. 0320 Extracorporeal Photopheresis Table of Contents Related Coverage Resources Overview .............................................................. 1 Heart, Lung and Heart-Lung Transplantation Coverage Policy ................................................... 1 Plasmapheresis General Background ............................................ 2 Medicare Coverage Determinations .................... 4 Coding/Billing Information .................................... 5 References .......................................................... 5 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For
    [Show full text]